1175 related articles for article (PubMed ID: 33035667)
1. Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers.
Cogswell PM; Wiste HJ; Senjem ML; Gunter JL; Weigand SD; Schwarz CG; Arani A; Therneau TM; Lowe VJ; Knopman DS; Botha H; Graff-Radford J; Jones DT; Kantarci K; Vemuri P; Boeve BF; Mielke MM; Petersen RC; Jack CR
Neuroimage; 2021 Jan; 224():117433. PubMed ID: 33035667
[TBL] [Abstract][Full Text] [Related]
2. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
[TBL] [Abstract][Full Text] [Related]
3. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
[TBL] [Abstract][Full Text] [Related]
4. Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease.
Cody KA; Langhough RE; Zammit MD; Clark L; Chin N; Christian BT; Betthauser TJ; Johnson SC
Brain; 2024 Jun; 147(6):2144-2157. PubMed ID: 38667631
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Susceptibility Mapping of Amyloid-β Aggregates in Alzheimer's Disease with 7T MR.
Tiepolt S; Schäfer A; Rullmann M; Roggenhofer E; ; Gertz HJ; Schroeter ML; Patt M; Bazin PL; Jochimsen TH; Turner R; Sabri O; Barthel H
J Alzheimers Dis; 2018; 64(2):393-404. PubMed ID: 29865069
[TBL] [Abstract][Full Text] [Related]
6. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
Betthauser TJ; Koscik RL; Jonaitis EM; Allison SL; Cody KA; Erickson CM; Rowley HA; Stone CK; Mueller KD; Clark LR; Carlsson CM; Chin NA; Asthana S; Christian BT; Johnson SC
Brain; 2020 Jan; 143(1):320-335. PubMed ID: 31886494
[TBL] [Abstract][Full Text] [Related]
7. Associations between quantitative [
Timmers T; Ossenkoppele R; Wolters EE; Verfaillie SCJ; Visser D; Golla SSV; Barkhof F; Scheltens P; Boellaard R; van der Flier WM; van Berckel BNM
Alzheimers Res Ther; 2019 Jul; 11(1):60. PubMed ID: 31272512
[TBL] [Abstract][Full Text] [Related]
8. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
9. Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.
Gordon BA; Blazey TM; Christensen J; Dincer A; Flores S; Keefe S; Chen C; Su Y; McDade EM; Wang G; Li Y; Hassenstab J; Aschenbrenner A; Hornbeck R; Jack CR; Ances BM; Berman SB; Brosch JR; Galasko D; Gauthier S; Lah JJ; Masellis M; van Dyck CH; Mintun MA; Klein G; Ristic S; Cairns NJ; Marcus DS; Xiong C; Holtzman DM; Raichle ME; Morris JC; Bateman RJ; Benzinger TLS
Brain; 2019 Apr; 142(4):1063-1076. PubMed ID: 30753379
[TBL] [Abstract][Full Text] [Related]
10. Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.
Quiroz YT; Sperling RA; Norton DJ; Baena A; Arboleda-Velasquez JF; Cosio D; Schultz A; Lapoint M; Guzman-Velez E; Miller JB; Kim LA; Chen K; Tariot PN; Lopera F; Reiman EM; Johnson KA
JAMA Neurol; 2018 May; 75(5):548-556. PubMed ID: 29435558
[TBL] [Abstract][Full Text] [Related]
11. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.
Buckley RF; Hanseeuw B; Schultz AP; Vannini P; Aghjayan SL; Properzi MJ; Jackson JD; Mormino EC; Rentz DM; Sperling RA; Johnson KA; Amariglio RE
JAMA Neurol; 2017 Dec; 74(12):1455-1463. PubMed ID: 28973551
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's pathology targets distinct memory networks in the ageing brain.
Maass A; Berron D; Harrison TM; Adams JN; La Joie R; Baker S; Mellinger T; Bell RK; Swinnerton K; Inglis B; Rabinovici GD; Düzel E; Jagust WJ
Brain; 2019 Aug; 142(8):2492-2509. PubMed ID: 31199481
[TBL] [Abstract][Full Text] [Related]
13. In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain.
Sepulcre J; Schultz AP; Sabuncu M; Gomez-Isla T; Chhatwal J; Becker A; Sperling R; Johnson KA
J Neurosci; 2016 Jul; 36(28):7364-74. PubMed ID: 27413148
[TBL] [Abstract][Full Text] [Related]
14. Quantitative susceptibility mapping in β-Amyloid PET-stratified patients with dementia and healthy controls - A hybrid PET/MRI study.
Tiepolt S; Rullmann M; Jochimsen TH; Gertz HJ; Schroeter ML; Patt M; Sabri O; Barthel H
Eur J Radiol; 2020 Oct; 131():109243. PubMed ID: 32916411
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous quantitative susceptibility mapping and Flutemetamol-PET suggests local correlation of iron and β-amyloid as an indicator of cognitive performance at high age.
van Bergen JMG; Li X; Quevenco FC; Gietl AF; Treyer V; Meyer R; Buck A; Kaufmann PA; Nitsch RM; van Zijl PCM; Hock C; Unschuld PG
Neuroimage; 2018 Jul; 174():308-316. PubMed ID: 29548847
[TBL] [Abstract][Full Text] [Related]
16. Association of
La Joie R; Visani AV; Lesman-Segev OH; Baker SL; Edwards L; Iaccarino L; Soleimani-Meigooni DN; Mellinger T; Janabi M; Miller ZA; Perry DC; Pham J; Strom A; Gorno-Tempini ML; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
Neurology; 2021 Feb; 96(5):e650-e661. PubMed ID: 33262228
[TBL] [Abstract][Full Text] [Related]
17. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O
Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987
[TBL] [Abstract][Full Text] [Related]
18. Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer's disease.
Halawa OA; Gatchel JR; Amariglio RE; Rentz DM; Sperling RA; Johnson KA; Marshall GA;
Alzheimers Res Ther; 2019 Jan; 11(1):14. PubMed ID: 30704519
[TBL] [Abstract][Full Text] [Related]
19. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
[TBL] [Abstract][Full Text] [Related]
20. Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis.
Zeydan B; Lowe VJ; Reichard RR; Przybelski SA; Lesnick TG; Schwarz CG; Senjem ML; Gunter JL; Parisi JE; Machulda MM; Vemuri P; Mielke MM; Knopman DS; Petersen RC; Jack CR; Kantarci OH; Kantarci K
Ann Neurol; 2020 Apr; 87(4):556-567. PubMed ID: 31970802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
